Biomea Fusion Inc (BMEA)

Biomea Fusion's stock price has decreased by 24.69% over the past six months and 70.74% over the past year. A positive market reaction followed the Q3 2025 earnings release on November 4, 2025, which included positive clinical data and financial updates. The company also participated in various healthcare conferences.

There is no direct information available regarding demand seasonality for Biomea Fusion's products and services. As a clinical-stage biopharmaceutical company with no approved commercial products, traditional product demand seasonality does not apply. The company's revenue is currently reported as $0.00 USD.

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing covalent small molecule drugs for genetically defined cancers and metabolic disorders like diabetes and obesity. Their lead product candidate, BMF-219 (icovamenib), is an oral menin inhibitor aimed at restoring insulin-producing beta cells. Their second development candidate, BMF-650, is a next-generation oral GLP-1 receptor agonist, projected to enter clinical studies in the second half of 2025.

Biomea Fusion, Inc. is a U.S.-based clinical-stage company headquartered in San Carlos, California. The company conducts its research and early clinical operations within the United States.

Biomea Fusion has a news sentiment score of 1.90, indicating generally positive news sentiment compared to the average for medical companies. Events contributing to its reputation include positive Phase II data for icovamenib, initiation of a Phase I study for BMF-650, and presentations of clinical data at scientific sessions.

Biomea Fusion, Inc. has 122 institutional owners and shareholders holding a total of 25,569,818 shares, representing 44.1% of the company's total outstanding shares. Major institutional owners include FMR LLC, Cormorant Asset Management, LP, and Vanguard Group Inc. Insiders own approximately 8.85% of the company's stock, while individual investors and public companies own 3.58%.